Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia
Standard
Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia : case report. / Orouji, Elias; Ziegler, Birgit; Umansky, Viktor; Gebhardt, Christoffer; Utikal, Jochen.
in: MEDICINE, Jahrgang 93, Nr. 28, 12.2014, S. e161.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia
T2 - case report
AU - Orouji, Elias
AU - Ziegler, Birgit
AU - Umansky, Viktor
AU - Gebhardt, Christoffer
AU - Utikal, Jochen
PY - 2014/12
Y1 - 2014/12
N2 - Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor 'dabrafenib? had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients' leukocytes despite similar clinical efficacy in melanoma.
AB - Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor 'dabrafenib? had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients' leukocytes despite similar clinical efficacy in melanoma.
KW - Antineoplastic Agents
KW - Female
KW - Humans
KW - Imidazoles
KW - Indoles
KW - Leukocyte Count
KW - Leukopenia
KW - Melanoma
KW - Middle Aged
KW - Oximes
KW - Proto-Oncogene Proteins B-raf
KW - Skin Neoplasms
KW - Sulfonamides
KW - Case Reports
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.1097/MD.0000000000000161
DO - 10.1097/MD.0000000000000161
M3 - SCORING: Journal article
C2 - 25526431
VL - 93
SP - e161
JO - MEDICINE
JF - MEDICINE
SN - 0025-7974
IS - 28
ER -